bullish
Pharmaessentia Corp (6446 TT): Besremi Starts 2023 on Strong Note; Geography Expansion Continues
547 Views15 Feb 2023 15:24
SUMMARY
- Pharmaessentia Corp (6446 TT) recorded revenue of NT$232M (+259% YoY) for its sole marketed product Besremi in January 2023. For 2022, Besremi reported revenue of NT$2.9B (+339% YoY).
- Thus far, Besremi received approval in US, EU, Switzerland, Israel, South Korea, Macao, and Taiwan. Besremi is expected to obtain approval in Japan and China in 2Q23 and 1Q24, respectively.
- Besremi is in phase 3 trial for essential thrombocythemia, which is a myeloproliferative neoplasm characterized by an overproduction of platelets in the blood resulting from a genetic mutation.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Starts 2024 on Strong Note; Reports First Operating Profit in 1Q2425 Jun 2024
- Pharmaessentia Corp (6446 TT): Readying for Next Growth Phase with Besremi’s Continued Traction07 Mar 2024
- Pharmaessentia Corp (6446 TT): Besremi Revenue Is Recovering; Fund Raising Through GDS Completed21 Jul 2023
- Pharmaessentia Corp (6446 TT): Riding High Aided by Continued Strong Uptake of Besremi in US14 Nov 2022
- Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down10 Aug 2022
- Pharmaessentia Corp (6446 TT): Key Drug Is Advancing Commercialization Globally05 May 2022
x